GlassScriptPhysician profile
Alicia Conn
NPI 1538604368
$4,625.46
in general payments reported to CMS, 2019-2025
16 companies · $20.49 in 2025
The $20.49 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $334 · 2022: $1,050 · 2023: $1,830 · 2024: $1,391 · 2025: $20.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,192 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,192.33 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,168.58 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $639.78 | 2021-2024 | Invega Sustenna, Spravato |
| Alkermes, INC. | $558.77 | 2021-2024 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $460.75 | 2021-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $444.69 | 2022-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $375.53 | 2022-2024 | Caplyta |
| Almatica Pharma LLC | $302.41 | 2022-2024 | Loreev Xr, Gralise |
| Axsome Therapeutics, INC. | $254.07 | 2023-2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $169.49 | 2022-2024 | Uzedy, Austedo Xr, Austedo |
| Astrazeneca Pharmaceuticals LP | $54.31 | 2021 | |
| Lundbeck LLC | $51.62 | 2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $45.76 | 2021 | |
| Bausch Health US, LLC | $32.23 | 2024 | Wellbutrin, Aplenzin |
| Boston Scientific Corporation | $28.77 | 2021 | |
| Indivior INC. | $23.89 | 2023 | Sublocade |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $14.81 | 2023 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia Conn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.